Valproic Acid and Its Effects on HIV Latent Reservoirs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine whether the co-administration of valproic acid (Epival®), with highly active antiretroviral therapy (HAART) can reduce the size of HIV latent reservoirs in infected CD4 cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Valproic Acid to Treat HIV Infected Adults

NCT00312546

HIV Infections

TERMINATED PHASE1

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

NCT00051831

HIV Infections

COMPLETED NA

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

NCT01440569

Acquired Immunodeficiency Syndrome HIV Infections

COMPLETED PHASE3

Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV

NCT05215704

HIV Infections HIV-1-infection HIV-2 Infection

RECRUITING

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

NCT06819176

Human Immunodeficiency Virus

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants must be on HAART with a suppressed viral load (\< 50 copies/ml) for at least the previous 12 months. They will be randomly assigned to one of two groups, one group will start the valproic acid right away at week 1 for 16 weeks, and the other group will wait until week 17 to add valproic acid to their treatment for 32 weeks. Subjects will be followed every four weeks for one year and evaluated by a variety of assays, all carried out using well-established methods, to assess the main outcome defined by changes in HIV reservoir size measured by the mean frequency of resting CD4 memory cells carrying HIV proviral DNA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.

Group Type EXPERIMENTAL

Valproic Acid

Intervention Type DRUG

Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.

HAART

Intervention Type DRUG

As per standard of care.

Group 2

HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.

Group Type EXPERIMENTAL

Valproic Acid

Intervention Type DRUG

Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.

HAART

Intervention Type DRUG

As per standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Valproic Acid

Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.

Intervention Type DRUG

HAART

As per standard of care.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Documented HIV seropositive infection by Western Blot, EIA assays or viral load.

* Aged 18 years old or older.
* Viral load \<50 copies/ml for at least the previous 12 months.
* Circulating CD4+ cell count ³ 200 cells/ml.
* Taking HAART.
* Vital signs, physical examination and laboratory results do not exhibit evidence of diseases such as advanced cirrhosis and advanced liver disease (ALT or AST \> 5 x upper limit of normal value).
* Karnofsky performance status 80%.
* Subject does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with VPA.
* Willing and able to give informed consent.
* All participants will agree to abstinence or to used effective methods of contraception while on the study.

Exclusion Criteria

* Pregnant or breast-feeding women.
* Psychiatric or cognitive disturbance or illness that could preclude compliance with the study.
* Current use or use within four weeks prior to the baseline visit, of cytotoxic agents, systemic corticosteroids or any immunomodulatory agents such as intravenous immunoglobulin, or hydroxyurea.
* HIV vaccine within six months of screening visit
* Allergic reaction to VPA.
* Active intravenous drug users.
* History of bleeding disorders.
* Unstable or treated hypertension.
* Past-history of pancreatitis or chronic liver disease (ALT or AST \> 5 x upper limit of normal value). However subject co-infected with hepatitis B or C can participate if ALT or AST is \< 5 x upper limit of normal value.
* Renal failure (creatinine \> 2 x upper limit of normal value).
* Ammonemia (\> 2x upper limit of normal value).
* Taking Zidovudine (AZT), or combination of drugs containing AZT like Combivir or Trizivir. However this subject will be asked to switch to another NRTI,at least two weeks prior to Valproic Acid initiation, to become eligible.
* Taking on daily basis: phenytoin, carbamazepine, phenobarbital, warfarin or aspirin.
* Subject has any of the following abnormal laboratory results Hemoglobin \< 100 g/L. Absolute neutrophil count \< 0.75 x 10 9 cells/L. Platelet count \< 50 x 10 9 cells/L.
* Subject suffering from urea cycle disorders.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No